Inhibitory compounds
Specific METTL1 inhibitors are developed to target the METTL1/WDR4 complex, addressing the limitations of current treatments for proliferative disorders like cancer, by reducing cell proliferation and enhancing anti-tumor immune responses.
WO2025104443A1 Publication Date: 2025-05-22STORM THERAPEUTICS LIMITED
15 Cites 2 Cited by
Patent Information
- Application Number
- PCT/GB2024/052898
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-08
- Filing Date
- 2024-11-14
- Publication Date
- 2025-05-22
AI Technical Summary
Technical Problem
Current treatments for proliferative disorders, such as cancer, are limited in effectively inhibiting METTL1 activity, which is associated with increased cell proliferation and poor prognosis in various cancer types.
Method used
Development of specific compounds that act as inhibitors of METTL1 activity, which can be used in pharmaceutical compositions to treat proliferative conditions, including cancer, by targeting the METTL1/WDR4 complex.
Benefits of technology
The proposed METTL1 inhibitors demonstrate potential in reducing cell proliferation, inhibiting metastasis, and enhancing anti-tumor immune responses, thereby offering a novel therapeutic approach for cancer treatment.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to compounds of Formula (I), defined herein, that function as inhibitors of METTL1 enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which METTL1 activity is implicated.
Need to check novelty before this filing date? Find Prior Art